TABLE 2.
Clinical outcomes in preintervention and postintervention periods
| Outcomea | Preintervention, n = 830 | Postintervention, n = 333 | P value |
|---|---|---|---|
| Empirical antimicrobial therapy within 48 h (n [%]) | |||
| Combination therapy | 225 (27) | 49 (15) | <0.001 |
| Antipseudomonal agents | 684 (82) | 252 (76) | 0.01 |
| Carbapenems | 89 (11) | 32 (10) | 0.57 |
| Appropriate empirical therapy within 48 h (n [%]) | |||
| Overall | 758 (91) | 317 (95) | 0.02 |
| Pitt bacteremia score of ≥4 | 170/190 (89) | 63/65 (97) | 0.06 |
| BSI due to P. aeruginosa/CAE | 134/154 (87) | 66/68 (97) | 0.02 |
| Time to de-escalation (median [IQR]) (days)b | |||
| Combination therapy | 2.8 (2.5–3.0) | 1.5 (1.0–2.0) | <0.001 |
| Antipseudomonal beta-lactams | 4.0 (3.6–4.2) | 2.5 (2.3–2.7) | <0.001 |
| Carbapenems | 4.0 (3.7–4.9) | 2.5 (2.0–3.0) | <0.001 |
a
CAE, AmpC-producing Enterobacteriaceae; IQR, interquartile range.
b
Number of subjects eligible for de-escalation in pre- and postintervention periods was 225 and 49 for combination therapy, 388 and 156 for antipseudomonal beta-lactams, and 181 and 52 for carbapenems, respectively.